Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation

<table class="table-group" id="tab6"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left" rowspan="2">Molecule</td><td class="align_center" colspan="2">Binding energy (kJ/mol)</td></tr><tr class="thead"><td class="align_center">Towards dopamine receptor D2</td><td class="align_center">Towards dopamine receptor D3</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Pramipexole</td><td class="align_center">83.021</td><td class="align_center">149.219</td></tr><tr><td class="align_left">Pramipexole mannose adduct</td><td class="align_center">−4.605</td><td class="align_center">−53.827</td></tr><tr><td class="align_left">Pramipexole ribose adduct</td><td class="align_center">−180.197</td><td class="align_center">−137.741</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Binding energy of pramipexole, pramipexole mannose adduct, and pramipexole ribose adduct towards dopamine receptor D2 and dopamine receptor D3.</div>

Advances in Pharmacological and Pharmaceutical Sciences

tab6

Table 6

Table 6: Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation 